ATE400289T1 - Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) - Google Patents

Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)

Info

Publication number
ATE400289T1
ATE400289T1 AT00905992T AT00905992T ATE400289T1 AT E400289 T1 ATE400289 T1 AT E400289T1 AT 00905992 T AT00905992 T AT 00905992T AT 00905992 T AT00905992 T AT 00905992T AT E400289 T1 ATE400289 T1 AT E400289T1
Authority
AT
Austria
Prior art keywords
vegf
growth factor
vascular endothelial
endothelial growth
antibodies
Prior art date
Application number
AT00905992T
Other languages
English (en)
Inventor
Craig Rosen
Ralph Alderson
Robert Melder
Viktor Roschke
Steven Ruben
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE400289T1 publication Critical patent/ATE400289T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
AT00905992T 1999-02-08 2000-02-07 Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) ATE400289T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11917999P 1999-02-08 1999-02-08
US11992699P 1999-02-12 1999-02-12
US13779699P 1999-06-03 1999-06-03
US17150599P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
ATE400289T1 true ATE400289T1 (de) 2008-07-15

Family

ID=27494239

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905992T ATE400289T1 (de) 1999-02-08 2000-02-07 Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)

Country Status (10)

Country Link
EP (2) EP1156820B1 (de)
JP (1) JP2002539082A (de)
KR (1) KR20010101981A (de)
CN (1) CN1433318A (de)
AT (1) ATE400289T1 (de)
AU (1) AU2757000A (de)
CA (1) CA2361615A1 (de)
DE (1) DE60039416D1 (de)
HK (1) HK1042052A1 (de)
WO (1) WO2000045835A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
EP1279406A4 (de) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd Transporters und arzneimittelabgabesysteme die diese verwenden
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
US20040254197A1 (en) * 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
EP1869075B1 (de) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Antiangiogene methoden und zusammensetzungen
ATE476986T1 (de) * 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
AU2018281871B2 (en) * 2017-06-07 2022-07-28 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN111291789B (zh) * 2020-01-19 2022-07-05 华东交通大学 基于多阶段多特征深度融合的乳腺癌图像识别方法及系统
WO2022047734A1 (zh) * 2020-09-04 2022-03-10 孔二艳 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
EP1985632A3 (de) 2008-11-12
EP1156820A1 (de) 2001-11-28
EP1156820A4 (de) 2004-12-22
DE60039416D1 (de) 2008-08-21
HK1042052A1 (zh) 2002-08-02
JP2002539082A (ja) 2002-11-19
EP1985632A2 (de) 2008-10-29
CA2361615A1 (en) 2000-08-10
KR20010101981A (ko) 2001-11-15
CN1433318A (zh) 2003-07-30
AU2757000A (en) 2000-08-25
WO2000045835A1 (en) 2000-08-10
EP1156820B1 (de) 2008-07-09

Similar Documents

Publication Publication Date Title
DE60039416D1 (de) Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2)
NO2019045I1 (no) Ranibizumab - Forlenget SPC
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
EP1042343A4 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
FR07C0017I2 (fr) Anticorps anti-vegf
FI962350A0 (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
ATE277034T1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69929041D1 (de) Verwendung von cabergolin zur behandlung von "restless legs syndrom"
DE69920031D1 (de) Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
DE69841041D1 (de) Stent beschichtet mit dna
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
DE69633980D1 (de) Verwendung von hyaluronsäure als immunsuppessor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties